Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Risk of Bias and Error From Data Sets Used for Dermatologic Artificial Intelligence

Risk of Bias and Error From Data Sets Used for Dermatologic Artificial Intelligence Editorial Opinion to severe plaque psoriasis (BE VIVID): efficacy and in a randomised, double-blind, placebo-controlled, 13. Langley RG, Tsai TF, Flavin S, et al. Efficacy and safety from a 52-week, multicentre, double-blind, phase III study in psoriatic arthritis. Ann Rheum Dis. safety of guselkumab in patients with psoriasis who active comparator and placebo controlled phase 3 2017;76(9):1550-1558. doi:10.1136/annrheumdis- have an inadequate response to ustekinumab: trial. Lancet. 2021;397(10273):487-498. doi:10. 2016-210724 results of the randomized, double-blind, phase III 1016/S0140-6736(21)00125-2 NAVIGATE trial. Br J Dermatol. 2018;178(1):114-123. 9. Matos TR, O’Malley JT, Lowry EL, et al. Clinically doi:10.1111/bjd.15750 5. Papp KA, Blauvelt A, Bukhalo M, et al. resolved psoriatic lesions contain psoriasis-specific Risankizumab versus ustekinumab for IL-17–producing αβ T cell clones. J Clin Invest.2017; 14. Visvanathan S, Baum P, Vinisko R, et al. moderate-to-severe plaque psoriasis. N Engl J Med. 127(11):4031-4041. doi:10.1172/JCI93396 Psoriatic skin molecular and histopathologic 2017;376(16):1551-1560. doi:10.1056/ profiles after treatment with risankizumab versus 10. Cheuk S, Wikén M, Blomqvist L, et al. NEJMoa1607017 ustekinumab. J Allergy Clin Immunol. 2019;143(6): Epidermal Th22 and Tc17 cells form a localized 2158-2169. doi:10.1016/j.jaci.2018.11.042 6. Torres T, Puig L, Vender R, et al. Drug survival of disease memory in clinically healed psoriasis. IL-12/23, IL-17 and IL-23 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Dermatology American Medical Association

Risk of Bias and Error From Data Sets Used for Dermatologic Artificial Intelligence

JAMA Dermatology , Volume 157 (11) – Nov 22, 2021

Loading next page...
 
/lp/american-medical-association/risk-of-bias-and-error-from-data-sets-used-for-dermatologic-artificial-5gKaHxJMna
Publisher
American Medical Association
Copyright
Copyright 2021 American Medical Association. All Rights Reserved.
ISSN
2168-6068
eISSN
2168-6084
DOI
10.1001/jamadermatol.2021.3128
Publisher site
See Article on Publisher Site

Abstract

Editorial Opinion to severe plaque psoriasis (BE VIVID): efficacy and in a randomised, double-blind, placebo-controlled, 13. Langley RG, Tsai TF, Flavin S, et al. Efficacy and safety from a 52-week, multicentre, double-blind, phase III study in psoriatic arthritis. Ann Rheum Dis. safety of guselkumab in patients with psoriasis who active comparator and placebo controlled phase 3 2017;76(9):1550-1558. doi:10.1136/annrheumdis- have an inadequate response to ustekinumab: trial. Lancet. 2021;397(10273):487-498. doi:10. 2016-210724 results of the randomized, double-blind, phase III 1016/S0140-6736(21)00125-2 NAVIGATE trial. Br J Dermatol. 2018;178(1):114-123. 9. Matos TR, O’Malley JT, Lowry EL, et al. Clinically doi:10.1111/bjd.15750 5. Papp KA, Blauvelt A, Bukhalo M, et al. resolved psoriatic lesions contain psoriasis-specific Risankizumab versus ustekinumab for IL-17–producing αβ T cell clones. J Clin Invest.2017; 14. Visvanathan S, Baum P, Vinisko R, et al. moderate-to-severe plaque psoriasis. N Engl J Med. 127(11):4031-4041. doi:10.1172/JCI93396 Psoriatic skin molecular and histopathologic 2017;376(16):1551-1560. doi:10.1056/ profiles after treatment with risankizumab versus 10. Cheuk S, Wikén M, Blomqvist L, et al. NEJMoa1607017 ustekinumab. J Allergy Clin Immunol. 2019;143(6): Epidermal Th22 and Tc17 cells form a localized 2158-2169. doi:10.1016/j.jaci.2018.11.042 6. Torres T, Puig L, Vender R, et al. Drug survival of disease memory in clinically healed psoriasis. IL-12/23, IL-17 and IL-23

Journal

JAMA DermatologyAmerican Medical Association

Published: Nov 22, 2021

References